Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass PathwaysFRA:5Y6 -3.85%40 Buyback Yield % is -8.90 as of Jul. 24, 2026. GuruFocus rates FRA:5Y6 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 274 Healthcare Providers & Services companies, Compass Pathways ranks worse than 76.28% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Compass Pathways's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5Y6 vs AGL, MD, SEM: Buyback Yield % Comparison
For the Medical Care Facilities subindustry, Compass Pathways's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (FRA:5Y6) has a Buyback Yield % of -8.90 as of Jul. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Compass Pathways and its competitors. According to the industry distribution chart, Compass Pathways ranks #209 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 76.3%.
Is Compass Pathways' Buyback Yield % too high?
Compass Pathways' current Buyback Yield % is -8.90. Based on the distribution chart, Compass Pathways ranks #209 out of 274 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Compass Pathways has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Buyback Yield % compare to AGL and MD?
According to the Healthcare Providers & Services industry distribution chart, Compass Pathways ranks #209 out of 274 companies for Buyback Yield %. This places Compass Pathways in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Compass Pathways and its competitors. Compass Pathways's current Buyback Yield % is -8.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (FRA:5Y6) has a current Buyback Yield % of -8.90. The current Buyback Yield % is -8.90. Compass Pathways' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Compass Pathways (FRA:5Y6), the current Buyback Yield % is -8.90 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
40GF Score
Get the complete analysis for FRA:5Y6
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5Y6 has been successfully added to your 
